IVD SECTOR QUARTERLIES ROUND-UP: Spending spree puts Inverness in red for Q4
This article was originally published in Clinica
Charges resulting from a busy year of acquisition and integration activities have led to Inverness Medical Systems posting a net loss for the fourth quarter of 2007. The Waltham, Massachusetts-based diagnostics specialist recorded a deficit of $12.5m, a significant drop compared to the profit of $6m it made over the same period in 2006. Inverness' fourth-quarter net revenue rose by 83% to approximately $288m, largely helped by contributions from acquired businesses which boosted sales of the company's professional diagnostics products. This core business segment generated $234.2m in revenue ($139.3m derived from acquired product lines), a sharp rise compared to the same period in 2006, during which it made $87.2m.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.